BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 8875971)

  • 1. A review of current clinical findings with fluvastatin.
    Garnett WR
    Am J Cardiol; 1996 Sep; 78(6A):20-5. PubMed ID: 8875971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
    Lennernäs H; Fager G
    Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meeting national cholesterol education goals in clinical practice--a comparison of lovastatin and fluvastatin in primary prevention.
    Nash DT
    Am J Cardiol; 1996 Sep; 78(6A):26-31. PubMed ID: 8875972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
    Plans-Rubió P
    Am J Cardiovasc Drugs; 2006; 6(3):177-88. PubMed ID: 16780391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in the treatment of patients with hypercholesterolemia: a meta-analysis of clinical trials.
    Kong SX; Crawford SY; Gandhi SK; Seeger JD; Schumock GT; Lam NP; Stubbings J; Schoen MD
    Clin Ther; 1997; 19(4):778-97. PubMed ID: 9377621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multicenter, randomized, double-blind clinical trial comparing the low-density lipoprotein cholesterol-lowering ability of lovastatin 10, 20, and 40 mg/d with fluvastatin 20 and 40 mg/d.
    Davidson MH; Palmisano J; Wilson H; Liss C; Dicklin MR
    Clin Ther; 2003 Nov; 25(11):2738-53. PubMed ID: 14693301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A preliminary report of the safety and efficacy of fluvastatin for hypercholesterolemia in renal transplant patients receiving cyclosporine.
    Goldberg RB; Roth D
    Am J Cardiol; 1995 Jul; 76(2):107A-109A. PubMed ID: 7604782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of fluvastatin and pravastatin on lipid profiles and thromboxane production in type IIa hypercholesterolemia.
    Milani M; Cimminiello C; Merlo B; Lorena M; Arpaia G; Bonfardeci G
    Am J Cardiol; 1995 Jul; 76(2):51A-53A. PubMed ID: 7604798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study).
    Jones P; Kafonek S; Laurora I; Hunninghake D
    Am J Cardiol; 1998 Mar; 81(5):582-7. PubMed ID: 9514454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluvastatin: a review of its pharmacology and use in the management of hypercholesterolaemia.
    Plosker GL; Wagstaff AJ
    Drugs; 1996 Mar; 51(3):433-59. PubMed ID: 8882381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Fluvastatin in the treatment of hyperlipoproteinemia, initial experience].
    Ceska R
    Vnitr Lek; 1996 Aug; 42(8):533-6. PubMed ID: 8967021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of fluvastatin, a totally synthetic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. FLUENT Study Group. Fluvastatin Long-Term Extension Trial.
    Zavoral JH; Haggerty BJ; Winick AG; Bergmann SD
    Am J Cardiol; 1995 Jul; 76(2):37A-40A. PubMed ID: 7604795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An economic analysis of the Atorvastatin Comparative Cholesterol Efficacy and Safety Study (ACCESS).
    Smith DG; McBurney CR
    Pharmacoeconomics; 2003; 21 Suppl 1():13-23. PubMed ID: 12648031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of fluvastatin on intermediate density lipoprotein (remnants) and other lipoprotein levels in hypercholesterolemia.
    Broyles FE; Walden CE; Hunninghake DB; Hill-Williams D; Knopp RH
    Am J Cardiol; 1995 Jul; 76(2):129A-135A. PubMed ID: 7604788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluvastatin in combination with other lipid-lowering agents.
    Jokubaitis LA
    Br J Clin Pract Suppl; 1994 Dec; (77):28-32. PubMed ID: 19496270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluvastatin in combination with other lipid-lowering agents.
    Jokubaitis LA
    Br J Clin Pract Suppl; 1996 Jan; 77A():28-32. PubMed ID: 8729588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluvastatin in primary hypercholesterolemia: efficacy and safety in patients at high risk. An analysis of a clinical trial database.
    Peters TK; Muratti EN; Mehra M
    Am J Med; 1994 Jun; 96(6A):79S-83S. PubMed ID: 8017471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of fluvastatin for safely lowering atherogenic lipids in renal transplant patients receiving cyclosporine.
    Holdaas H; Hartmann A; Stenstrøm J; Dahl KJ; Borge M; Pfister P
    Am J Cardiol; 1995 Jul; 76(2):102A-106A. PubMed ID: 7604781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simvastatin compared to fluvastatin in the reduction of serum lipids and apolipoproteins in patients with ischaemic heart disease and moderate hypercholesterolaemia.
    Sigurdsson G; Haraldsdottir SO; Melberg TH; Tikkanen MJ; Miettinen TE; Kristianson KJ
    Acta Cardiol; 1998; 53(1):7-14. PubMed ID: 9638964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.